NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

重症肌無力(MG):流行病學的預測 ∼2027年

Myasthenia Gravis - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 534921
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 2-10個工作天內
價格
重症肌無力(MG):流行病學的預測 ∼2027年 Myasthenia Gravis - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 50 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的重症肌無力(MG)的總患病數2016年估計為12萬9,267人。

本報告提供重症肌無力(MG)的相關調查,疾病概要,患者背景,主要7個國家重症肌無力(MG)的患病數、診斷數的預測(今後10年份),市場成長機會等資訊。

目錄

第1章 重要洞察

第2章 重症肌無力:市場概要

第3章 市場佔有率、重症肌無力的分佈(最新值)

第4章 市場佔有率、重症肌無力的分佈(預測值)

第5章 疾病概要:重症肌無力

  • 簡介
  • 重症肌無力的種類
  • 重症肌無力:MGFA分類
  • 病因
  • 重症肌無力的遺傳性概要
  • 風險因素
  • 徵兆與症狀
  • 重症肌無力的病理生理學
  • 重症肌無力合併症
  • 診斷

第6章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 主要7個國家的整體患者人口
  • 重症肌無力的流行病學:各國
    • 美國
    • 前提和根據
    • 重症肌無力的患病數
    • 重症肌無力的患病數:性別
    • 重症肌無力的診斷數
    • 重症肌無力的診斷數:各重症度
    • 重症肌無力的診斷數:各自身抗體
  • 德國
    • 前提和根據
    • 重症肌無力的患病數
    • 重症肌無力的患病數:性別
    • 重症肌無力的診斷數
    • 重症肌無力的診斷數:各重症度
    • 重症肌無力的診斷數:各自身抗體
  • 法國
    • 前提和根據
    • 重症肌無力的患病數
    • 重症肌無力的患病數:性別
    • 重症肌無力的診斷數
    • 重症肌無力的診斷數:各重症度
    • 重症肌無力的診斷數:各自身抗體
  • 義大利
    • 前提和根據
    • 重症肌無力的患病數
    • 重症肌無力的患病數:性別
    • 重症肌無力的診斷數
    • 重症肌無力的診斷數:各重症度
    • 按重症肌無力的診斷數:自身抗體
  • 西班牙
    • 前提和根據
    • 重症肌無力的患病數
    • 重症肌無力的患病數:性別
    • 重症肌無力的診斷數
    • 重症肌無力的診斷數:各重症度
    • 重症肌無力的診斷數:各自身抗體
  • 日本
    • 前提和根據
    • 重症肌無力的患病數
    • 重症肌無力的患病數:性別
    • 重症肌無力的診斷數
    • 重症肌無力的診斷數:各重症度
    • 重症肌無力的診斷數:各自身抗體

第7章 市場成長要素

第8章 市場阻礙因素

第9章 附錄

第10章 報告方法

第11章 DelveInsight的服務內容

第12章 免責聲明

第13章 關於DelveInsight

目錄
Product Code: DIEI0145

DelveInsight's "Myasthenia Gravis - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Myasthenia Gravis epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

  • United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2016-2028

Myasthenia Gravis Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Myasthenia Gravis in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Myasthenia Gravis outlook. It also includes the explanation of changing trends of epidemiology outlining the Myasthenia Gravis scenario.

Myasthenia Gravis Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Myasthenia Gravis thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

  • The report covers detailed overview of Myasthenia Gravis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Myasthenia Gravis Report assesses the disease risk and burden and highlights the unmet needs
  • It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Total Cases in Myasthenia Gravis

Key assessments

  • Patient Segmentation in Myasthenia Gravis
  • Myasthenia Gravis Risk & Burden
  • Factors driving growth in a specific Myasthenia Gravis patient population

Table of Contents

1. Report Introduction

2. Myasthenia Gravis Epidemiology Overview at a Glance

  • 2.1. Patient Share Distribution of Myasthenia Gravis in 2016
  • 2.2. Patient Share Distribution of Myasthenia Gravis in 2028

3. Disease Background and Overview: Myasthenia Gravis

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Etiology
  • 3.4. Risk Factors
  • 3.5. Pathophysiology
  • 3.6. Diagnosis
  • 3.7. Treatment

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM
  • 4.3. Total Prevalent/ Incident Patient Population of Myasthenia Gravis in 7MM - By Countries

5. Epidemiology of Myasthenia Gravis by Countries

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.1.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.1.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.1.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.2. EU5
  • 5.3. Assumptions and Rationale
  • 5.4. Germany
    • 5.4.1. Assumptions and Rationale
    • 5.4.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.4.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.4.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.4.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.5. France
    • 5.5.1. Assumptions and Rationale
    • 5.5.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.5.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.5.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.5.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.6. Italy
    • 5.6.1. Assumptions and Rationale
    • 5.6.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.6.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.6.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.6.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.7. Spain
    • 5.7.1. Assumptions and Rationale
    • 5.7.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.7.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.7.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.7.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.8. United Kingdom
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.8.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.8.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.8.5. Diagnosed Cases of the Myasthenia Gravis
  • 5.9. Japan
    • 5.9.1. Assumptions and Rationale
    • 5.9.2. Prevalent/Incident Cases of the Myasthenia Gravis
    • 5.9.3. Sub-Type Specific cases of the Myasthenia Gravis *
    • 5.9.4. Sex- Specific Cases of the Myasthenia Gravis *
    • 5.9.5. Diagnosed Cases of the Myasthenia Gravis

6. Unmet Needs of the Myasthenia Gravis

7. Appendix

8. Report Methodology

  • 8.1. Sources

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Indication Specific

List of Tables

  • Table 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
  • Table 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
  • Table 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)*
  • Table 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)*
  • Table 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
  • Table 7: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 8: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Table 9: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Table 10: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Table 11: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 12: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028) *
  • Table 13: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028) *
  • Table 14: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
  • Table 15: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 16: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Table 17: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Table 18: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Table 19: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 20: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Table 21: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Table 22: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Table 23: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 24: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028) *
  • Table 25: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028) *
  • Table 26: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
  • Table 27: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Table 28: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Table 29: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Table 30: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)

List of Figures

  • Figure 1: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM
  • Figure 2: Total Prevalent/Incident Cases of the Myasthenia Gravis in 7MM by Countries
  • Figure 3: Prevalent/Incident Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 4: Sub-Type Specific cases of the Myasthenia Gravis in United States (2016-2028)*
  • Figure 5: Sex- Specific Cases of the Myasthenia Gravis in United States (2016-2028)*
  • Figure 6: Diagnosed Cases of the Myasthenia Gravis in United States (2016-2028)
  • Figure 7: Prevalent/Incident Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 8: Sub-Type Specific cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Figure 9: Sex- Specific Cases of the Myasthenia Gravis in Germany (2016-2028) *
  • Figure 10: Diagnosed Cases of the Myasthenia Gravis in Germany (2016-2028)
  • Figure 11: Prevalent/Incident Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 12: Sub-Type Specific cases of the Myasthenia Gravis in France (2016-2028) *
  • Figure 13: Sex- Specific Cases of the Myasthenia Gravis in France (2016-2028) *
  • Figure 14: Diagnosed Cases of the Myasthenia Gravis in France (2016-2028)
  • Figure 15: Prevalent/Incident Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 16: Sub-Type Specific cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Figure 17: Sex- Specific Cases of the Myasthenia Gravis in Italy (2016-2028) *
  • Figure 18: Diagnosed Cases of the Myasthenia Gravis in Italy (2016-2028)
  • Figure 19: Prevalent/Incident Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 20: Sub-Type Specific cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Figure 21: Sex- Specific Cases of the Myasthenia Gravis in Spain (2016-2028) *
  • Figure 22: Diagnosed Cases of the Myasthenia Gravis in Spain (2016-2028)
  • Figure 23: Prevalent/Incident Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 24: Sub-Type Specific cases of the Myasthenia Gravis in UK (2016-2028) *
  • Figure 25: Sex- Specific Cases of the Myasthenia Gravis in UK (2016-2028) *
  • Figure 26: Diagnosed Cases of the Myasthenia Gravis in UK (2016-2028)
  • Figure 27: Prevalent/Incident Cases of the Myasthenia Gravis in Japan (2016-2028)
  • Figure 28: Sub-Type Specific cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Figure 29: Sex- Specific Cases of the Myasthenia Gravis in Japan (2016-2028) *
  • Figure 30: Diagnosed Cases of the Myasthenia Gravis in Japan (2016-2028)